Currently, Krystal Biotech Inc [KRYS] is trading at $178.13, down -1.59%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The KRYS shares have lost -2.53% over the last week, with a monthly amount drifted -1.07%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Krystal Biotech Inc [NASDAQ: KRYS] stock has seen the most recent analyst activity on March 05, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $245. Previously, Citigroup downgraded its rating to Neutral on August 06, 2024, and elevated its price target to $204. On November 20, 2023, Goldman initiated with a Buy rating and assigned a price target of $160 on the stock. Cantor Fitzgerald started tracking the stock assigning a Overweight rating and suggested a price target of $100 on October 24, 2023. Citigroup initiated its recommendation with a Buy and recommended $160 as its price target on October 12, 2023. Berenberg started tracking with a Buy rating for this stock on September 07, 2023, and assigned it a price target of $154. In a note dated April 18, 2023, Stifel initiated an Buy rating and provided a target price of $102 on this stock.
This stock has fluctuated between a low of $141.72 and a high of $219.34 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $191 within the next 12 months. Krystal Biotech Inc [NASDAQ: KRYS] shares were valued at $178.13 at the most recent close of the market. An investor can expect a potential return of 7.23% based on the average KRYS price forecast.
Analyzing the KRYS fundamentals
Trailing Twelve Months sales for Krystal Biotech Inc [NASDAQ:KRYS] were 290.51M which represents 116.26% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.33%, and Net Profit Margin reading is 0.31%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.1 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 172.28 points at the first support level, and at 166.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 181.68, and for the 2nd resistance point, it is at 185.22.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Krystal Biotech Inc [NASDAQ:KRYS] is 7.28. As well, the Quick Ratio is 7.02, while the Cash Ratio is 3.38. Considering the valuation of this stock, the price to sales ratio is 17.66, the price to book ratio is 5.42 and price to earnings (TTM) ratio is 59.62.
Transactions by insiders
Recent insider trading involved Krishnan Suma, President, R&D, that happened on Mar 13 ’25 when 25000.0 shares were sold. President, R&D, Krishnan Suma completed a deal on Mar 13 ’25 to sell 25000.0 shares. Meanwhile, President and CEO Krishnan Krish S sold 25000.0 shares on Mar 13 ’25.
